Literature DB >> 21924083

[Characteristics of in-hospital patients with chronic heart failure in Hubei province from 2000 to 2010].

Sheng-Bo Yu1, Hong-Ying Cui, Mu Qin, Bin Kong, Tao Liu, Qing-Yan Zhao, He Huang, Bo Yang, Cong-Xin Huang.   

Abstract

OBJECTIVE: To evaluate the current status of chronic heart failure (CHF) in Hubei province and analyze the epidemiology of CHF including the general condition, etiology and pharmacological therapy.
METHODS: Data of in-hospital patients with CHF were investigated between 2000 and 2010 from 12 hospitals in Hubei Province. INCLUSION CRITERIA: over 18 years of age, organic heart disease and with the symptom of HF including dyspnea and fatigue. Patients with a history of myocardial infarction in the prior 12 months, congenital heart disease, pericardial disease and the history of cancer were excluded.
RESULTS: (1) A total of 12 450 patients were enrolled (7166 male, 57.56%). The average age was (62.0 ± 14.5) years. Patients in the scale of age ≥ 80, 70 - 79, 60 - 69, 50 - 59, 40 - 49 and < 40 was 9.53% (1187/12 450), 30.80% (3835/12 450), 23.45% (2920/12 450), 18.81% (2342/12 450), 10.73% (1336/12 450) and 6.67% (830/12 450), respectively (P < 0.01). The NYHA class I, II, III and IV was 0.60%, 23.20%, 50.31% and 26.50%, respectively. (2) The age of patients was significant reduced from 2000 - 2003, 2004 - 2006 to 2007 - 2010 [(66.4 ± 14.1) years, (64.9 ± 14.4) years and (64.2 ± 14.8) years, P < 0.01]. (3) The major causes of CHF were hypertension (31.54%), coronary heart disease (28.24%), dilated cardiomyopathy (26.57%) and rheumatic valvular heart disease (17.49%). The most frequent etiology for CHF was rheumatic valvular heart disease in patients aged less than 40 years old, dilated cardiomyopathy in patients aged 40 - 49 and 50 - 59 years and hypertension in patients aged 60-69, 70-79 and ≥ 80 years. (4) Drug use was as follows: Digitalis (47.49%), diuretics (68.75%), ACEI (50.66%), β-blocker (44.06%) and aldosterone antagonist (53.08%). Use of digitalis (Wald χ(2) = 903.41, P < 0.01;r = 0.271, P < 0.01), diuretics (Wald χ(2) = 818.05, P < 0.01; r = 0.249, P < 0.01), aldosterone antagonists (Wald χ(2) = 76.92, P < 0.01; r = 0.091, P < 0.01) increased while the β-blocker (Wald χ(2) = 160.65, P < 0.01; r = -0.117, P < 0.01) declined in proportion to NYHA class increase.
CONCLUSIONS: The age of in-hospital patients with CHF declined in the previous 10 years. The primary etiology was hypertension for aged CHF in-hospital patients with CHF. There was big gap between guideline recommended standard therapy and current drug use for in-hospital patients with CHF in Hubei province.

Entities:  

Mesh:

Year:  2011        PMID: 21924083

Source DB:  PubMed          Journal:  Zhonghua Xin Xue Guan Bing Za Zhi        ISSN: 0253-3758


  5 in total

1.  The Fasa Registry on Systolic Heart Failure (FaRSH): Feasibility Study and the First 5-year Reports.

Authors:  Mohammad Hosein Yazdanpanah; Ehsan Bahramali; Maryam Kazemi; Negar Firouzabadi; Peyman Arasteh; Reza Homayounfar; Alireza Sepehri Shamloo; Mojtaba Farjam
Journal:  Galen Med J       Date:  2021-09-02

2.  Evolvement of left ventricular assist device: the implications on heart failure management.

Authors:  Sek Ying Chair; Doris Sf Yu; Michael Timothy Ng; Qun Wang; Ho Yu Cheng; Eliza Ml Wong; Janet Wh Sit
Journal:  J Geriatr Cardiol       Date:  2016-07       Impact factor: 3.327

3.  Characteristics, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: The China PEACE Retrospective Heart Failure Study.

Authors:  Yuan Yu; Aakriti Gupta; Chaoqun Wu; Frederick A Masoudi; Xue Du; Jian Zhang; Harlan M Krumholz; Jing Li
Journal:  J Am Heart Assoc       Date:  2019-08-21       Impact factor: 5.501

4.  Patient-level comparison of heart failure patients in clinical phenotype and prognosis from China and Sweden.

Authors:  Yizhou Feng; Xiaojing Chen; Maria Schaufelberger; Qing Zhang; Michael Fu
Journal:  BMC Cardiovasc Disord       Date:  2022-03-08       Impact factor: 2.298

Review 5.  Heart failure in East Asia.

Authors:  Yutao Guo; Gregory Y H Lip; Amitava Banerjee
Journal:  Curr Cardiol Rev       Date:  2013-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.